1

Examine This Report on Journal of Leukemia Research

News Discuss 
Together with azacitidine or decitabine, or reduced-dose cytarabine in freshly diagnosed AML aged ≥ seventy five a long time or with co-morbidities that preclude the usage of intensive induction chemotherapy While acute leukemia needs to be addressed right away, Continual forms are sometimes monitored for a while ahead of treatment https://directivepublications.org/journal-of-leukemia-research/

Comments

    No HTML

    HTML is disabled


Who Upvoted this Story